{"title":"根据DIN EN ISO 15197:2015对血糖自我监测系统GL50 evo和GL 44的系统准确性评价:葡萄糖浓度范围< 100mg /dL和≥100mg /dL的准确性比较","authors":"E. Salzsieder, S. Berg, A. Puchert, E. Freyse","doi":"10.15761/imm.1000383","DOIUrl":null,"url":null,"abstract":"Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continues performance of self-monitoring blood glucose (SMBG) systems. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015,2 for which mandatory compliance is recommended for SMBG systems by 2015,3 has tighter accuracy requirements than ISO 15197:2003,4 and outlines current minimum accuracy standards necessary in Europe for CE marking. Introduction In the present study, a post marketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of both systems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3, A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was conducted from April 21 to May 05, 2015, at the Institute of Diabetes “Gerhardt Katsch,” Karlsburg, Germany. Ethical approval for the study was obtained from the Ethics Committee of the University of Greifswald in July 2014 [1-3]. Ear lobe capillary blood samples were taken from 118 subjects for duplicate glucose determination using the GL50 evo and the glucose oxidase based YSI2300 STAT PLUS (YSI Incorporated, Yellow Springs, Ohio, USA) plasma glucose reference method. Trueness and precision of the comparison assay were verified using a range of YSI bioanalytical standards and controls. The prescribed limits for the hematocrit values, to be between 20% and 60%, were reached by the patient samples and after examination of glucose concentration ranges using the YSI, 100 subjects were included in the analysis of accuracy [4]. In the glucose range <100 mg/dL in summary 98.8 % of the values and in the range ≥ 100 mg/dl in summary 98.6 % full filled the quality criteria of the ISO 15197. Important differences between the three tested lots were not shown; detailed data are presented in Tables 1 and *Correspondence to: Eckhard Salzsieder, Institute of Diabetes, Gerhardt Katsch, Karlsburg, Germany, E-mail: apuchert@diabetes-karlsburg.de","PeriodicalId":94322,"journal":{"name":"Integrative molecular medicine","volume":"480 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"System accuracy evaluation of the systems for self-monitoring of blood glucose GL50 evo and GL 44 following DIN EN ISO 15197:2015: A comparison of accuracy in glucose concentration ranges <100 mg/dL and ≥100 mg/dL\",\"authors\":\"E. Salzsieder, S. Berg, A. Puchert, E. Freyse\",\"doi\":\"10.15761/imm.1000383\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continues performance of self-monitoring blood glucose (SMBG) systems. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015,2 for which mandatory compliance is recommended for SMBG systems by 2015,3 has tighter accuracy requirements than ISO 15197:2003,4 and outlines current minimum accuracy standards necessary in Europe for CE marking. Introduction In the present study, a post marketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of both systems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3, A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was conducted from April 21 to May 05, 2015, at the Institute of Diabetes “Gerhardt Katsch,” Karlsburg, Germany. Ethical approval for the study was obtained from the Ethics Committee of the University of Greifswald in July 2014 [1-3]. Ear lobe capillary blood samples were taken from 118 subjects for duplicate glucose determination using the GL50 evo and the glucose oxidase based YSI2300 STAT PLUS (YSI Incorporated, Yellow Springs, Ohio, USA) plasma glucose reference method. Trueness and precision of the comparison assay were verified using a range of YSI bioanalytical standards and controls. The prescribed limits for the hematocrit values, to be between 20% and 60%, were reached by the patient samples and after examination of glucose concentration ranges using the YSI, 100 subjects were included in the analysis of accuracy [4]. In the glucose range <100 mg/dL in summary 98.8 % of the values and in the range ≥ 100 mg/dl in summary 98.6 % full filled the quality criteria of the ISO 15197. Important differences between the three tested lots were not shown; detailed data are presented in Tables 1 and *Correspondence to: Eckhard Salzsieder, Institute of Diabetes, Gerhardt Katsch, Karlsburg, Germany, E-mail: apuchert@diabetes-karlsburg.de\",\"PeriodicalId\":94322,\"journal\":{\"name\":\"Integrative molecular medicine\",\"volume\":\"480 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrative molecular medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/imm.1000383\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative molecular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/imm.1000383","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
对启动后用于自我监测的血糖仪系统的准确性进行持续的标准化验证具有重要的临床意义,并有助于确认自我监测血糖(SMBG)系统的适当持续性能。此外,此类研究的发表正日益成为基于证据的购买决策的一个组成部分。ISO 15197:2015,2到2015年强制要求SMBG系统遵守,3比ISO 15197:2003有更严格的精度要求,4并概述了欧洲CE标志所需的当前最低精度标准。在本研究中,根据ISO 15197:2015协议和要求,对ce标记的GL50 evo和GL44系统进行了上市后评估。GL50 evo和GL44系统由德国Beurer GmbH提供。在研究开始之前,两种测量系统的制造商提供了符合性声明,因此在测试中仅使用GL50 evo,但结果记录了两种系统的质量。制造商提供了两个GL50 evo系统(序列号:GL55 T1和GL55 T2)和3个不同批次(A 10/1, A 10/3, A 10/4)的条带,有效期分别为2017年3月)。该研究于2015年4月21日至5月5日在德国卡尔斯堡的糖尿病“Gerhardt Katsch”研究所进行。该研究于2014年7月获得Greifswald大学伦理委员会的伦理批准[1-3]。采用GL50 evo和基于葡萄糖氧化酶的YSI2300 STAT PLUS (YSI Incorporated, Yellow Springs, Ohio, USA)血浆血糖参比法,采集118例受试者耳垂毛细血管血样进行重复血糖测定。使用一系列YSI生物分析标准品和对照品验证了比较分析的准确性和精确性。患者样本的红细胞压积值达到规定的20%至60%的限度,使用YSI检查葡萄糖浓度范围后,将100名受试者纳入准确性[4]分析。在葡萄糖<100 mg/dL的范围内,98.8%的值符合ISO 15197的质量标准,在≥100 mg/dL的范围内,98.6%的值符合ISO 15197的质量标准。三个测试批次之间的重要差异没有显示出来;通讯:Eckhard salzsider,糖尿病研究所,Gerhardt Katsch, Karlsburg, Germany, E-mail: apuchert@diabetes-karlsburg.de
System accuracy evaluation of the systems for self-monitoring of blood glucose GL50 evo and GL 44 following DIN EN ISO 15197:2015: A comparison of accuracy in glucose concentration ranges <100 mg/dL and ≥100 mg/dL
Ongoing standardized verification of the accuracy of blood glucose meters systems for self-monitoring post-launch is important clinically and helps confirm appropriate continues performance of self-monitoring blood glucose (SMBG) systems. In addition, publication of such studies is increasingly becoming a component of evidence-based purchase decision making. ISO 15197:2015,2 for which mandatory compliance is recommended for SMBG systems by 2015,3 has tighter accuracy requirements than ISO 15197:2003,4 and outlines current minimum accuracy standards necessary in Europe for CE marking. Introduction In the present study, a post marketing evaluation of the CE-marked GL50 evo and GL44 systems were performed in accordance with ISO 15197:2015 protocols and requirements. The GL50 evo and GL44 systems were supplied in Germany from the Beurer GmbH, Germany. A declaration of conformity from the manufacturer of the two measuring systems was available before the start of the study, so that only the GL50 evo was used in the tests, but the results documented the quality of both systems. Two GL50 evo systems (serial number: GL55 T1 and GL55 T2) and strips from 3 different lots (A 10/1, A 10/3, A 10/4) with expiry dates March 2017 respectively) were supplied by the manufacturer. The study was conducted from April 21 to May 05, 2015, at the Institute of Diabetes “Gerhardt Katsch,” Karlsburg, Germany. Ethical approval for the study was obtained from the Ethics Committee of the University of Greifswald in July 2014 [1-3]. Ear lobe capillary blood samples were taken from 118 subjects for duplicate glucose determination using the GL50 evo and the glucose oxidase based YSI2300 STAT PLUS (YSI Incorporated, Yellow Springs, Ohio, USA) plasma glucose reference method. Trueness and precision of the comparison assay were verified using a range of YSI bioanalytical standards and controls. The prescribed limits for the hematocrit values, to be between 20% and 60%, were reached by the patient samples and after examination of glucose concentration ranges using the YSI, 100 subjects were included in the analysis of accuracy [4]. In the glucose range <100 mg/dL in summary 98.8 % of the values and in the range ≥ 100 mg/dl in summary 98.6 % full filled the quality criteria of the ISO 15197. Important differences between the three tested lots were not shown; detailed data are presented in Tables 1 and *Correspondence to: Eckhard Salzsieder, Institute of Diabetes, Gerhardt Katsch, Karlsburg, Germany, E-mail: apuchert@diabetes-karlsburg.de